NEW YORK (Dow Jones)-- Amgen Inc . (AMGN) reported a 24% rise in third-quarter profits, easily beating expectations, driven by cost cuts and strong sales on most major products. The strong earnings prompted the Thousand Oaks, Calif., drug maker to again raise its 2009 profit expectations and back its revenue projections. But the focus surrounding Amgen remains on the company's experimental bone drug denosumab. Amgen said with its earnings report Wednesday that the Food and Drug Administratio